Goldman Sachs Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Graig Suvannavejh maintains a Neutral rating on Halozyme Therapeutics (NASDAQ:HALO) and raises the price target from $44 to $49.
July 22, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Halozyme Therapeutics but raised the price target from $44 to $49, indicating a positive outlook despite the neutral stance.
The raised price target from $44 to $49 by Goldman Sachs suggests a positive outlook for Halozyme Therapeutics, which could lead to a short-term increase in stock price despite the Neutral rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100